A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

Inclusion Criteria:

- has T2DM

- (1) Male; (2) female not of reproductive potential; or (3) female of reproductive
potential who agrees to remain abstinent or use alone or in conjunction with their
partner 2 methods of contraception to prevent pregnancy during the study and for 14
days after the last dose of study drug

- is currently on metformin monotherapy at a daily dose of at least 1500 mg for at
least 10 weeks

- is not on a lipid-lowering agent for at least 6 weeks prior to entering the study

Exclusion Criteria:

- has history of type 1 diabetes mellitus (T1DM), or a history of ketoacidosis or
possibly has T1DM

- has been on a thiazolidinedione (TZD) within the previous 16 weeks

- has been treated with a statin or other lipid-lowering agent (including
over-the-counter [OTC] supplements) within the previous 6 weeks

- currently participating in or has participated in another clinical study within the
past 12 weeks

- intends to consume >1.2 liters of grapefruit juice daily during the study

- is on or likely to require treatment for over 2 consecutive weeks or repeated courses
of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)

- intolerance or hypersensitivity to sitagliptin, simvastatin, metformin or glimepiride

- is on a weight loss program and not in the maintenance phase or has started a weight
loss medication or has undergone bariatric surgery in the previous 12 months

- has undergone a surgical procedure in the past 4 weeks or planned major surgery
during the study

- has symptomatic hyperglycemia that requires immediate initiation, adjustment, or
addition of antihyperglycemic therapy

- has a history of myopathy or rhabdomyolysis with any statin

- has cardiovascular disease, a diagnosis of congestive heart failure, or uncontrolled
high blood pressure

- has a history of active liver disease

- has chronic progressive neuromuscular disorder, human immunodeficiency virus (HIV),
hematological disorder, or uncontrolled endocrine or metabolic disease

- is currently being treated for hyperthyroidism or is on thyroid hormone therapy and
has not been on a stable dose for at least 6 weeks

- has a history of malignancy in the previous 5 years (excluding adequately treated
basal cell or squamous cell skin cancer or in situ cervical cancer)

- is pregnant or breast feeding, or is expecting to conceive or donate eggs during the
course of the study, including 14 days after the last dose of study drug

- is a user of recreational or illicit drugs or has had a recent history of drug abuse

- consumes > 2 alcoholic drinks per day or > 14 alcoholic drinks per week, or engages
in binge drinking